| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-09-2024 | 03-31-2024 | 10-Q | |
| 2 | 03-26-2024 | 12-31-2023 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price tar...
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.36) per share. This is a 88.82 percent increase over losses of $(3.2...
Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.
HC Wainwright & Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price tar...
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolyt...
Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.
CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a po...
